Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of illness in North America and Europe (SABINE) study

Annals of Oncology

Volumn 23, Issue 10, 2012, Pages 2763-2770

  Leahy, M ^a   Garcia del muro, X ^b   Reichardt, P ^c   Judson, I ^d   Staddon, A ^e   Verweij, J ^f   Baffoe Bonnie, A ^g   Jonsson L ^h   Musayev, A ^h   Justo, N ^h   Burke, T ^g   Blay, J Y ⁱ   Reichardt, Annette ^j   Bauer, Sebastian ^k   Rauhut, Sahra ^k   Wendtner, Clemens ^l   Pester, Lars ^l   Sebag, William ^m   Goldwasser, Francois ⁿ   Jepiral, Wilana ⁿ   Chaigneau, Loïc ^o   Roy, Ludivine ^o   Bui Nguyen, Binh ^p   Albert, Sabrina ^p   Basso, Umberto ^q   Roma, Anna ^q   Ferraresi, Virgina ^r   Tedeschi, Maria ^r   Marchesi, Emanuela ^s   Verweij, Jaap ^f   Mol, Marianne ^f   Juliette Kamphuis ^t   Herraéz, Antonio Casado ^u   Peleteiro, Hortensia ^u   Laura Jimenez ^b   Maria Gajete ^v   López Pousa, Antonio ^w   Sanchez, Rosa ^w   Hagberg, Hans ^x   Chu, Quincy ^y   Miller, Margo ^y   Chawla, Sant P ^z   Chu, Victoria ^z   Staddon, Arthur ^aa   Burns, Zackory ^aa   Samuels, Brian ^ab   Dobler, Ryan ^ab   Gustin, Robin ^ab   Welby, Sarah ^a   Judson, Ian ^ac   Petrikova, Galina ^ac   Hayward, Larry ^ad   Ramage, Paul ^ad   more..

^a CHRISTIE HOSPITAL   (United Kingdom)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c HELIOS Klinikum Bad Saarow   (Germany)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e Pennsylvania Oncology Hematology Associates   (United States)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g MERCK RESEARCH LABORATORIES   (United States)

^h OptumInsight   (Sweden)

ⁱ UNIVERSITÉ LYON 1   (France)

^j Helios Klinikum   (Germany)

^k UNIVERSITY HOSPITAL ESSEN   (Germany)

^l UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^m EDOUARD HERRIOT HOSPITAL   (France)

ⁿ université Paris Cité   (France)

^o UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^p INSTITUT BERGONIÉ   (France)

^q VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^r REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^s RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^t LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^u HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^v HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^w HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^x UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^y UNIVERSITY OF ALBERTA   (Canada)

^z Sarcoma Oncology Center   (United States)

^aa Pennsylvania Oncology and Hematology Association   (United States)

^ab Kootenai Cancer Center   (United States)

^ac ROYAL MARSDEN HOSPITAL   (United Kingdom)

^ad UNIVERSITY OF EDINBURGH   (United Kingdom)

more..

Author keywords

Chemotherapy; Palliative care; Retrospective studies; Sarcoma; Soft tissue neoplasms

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BRIVANIB; BROSTALLICIN; CONATUMUMAB; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; IFOSFAMIDE; OMBRABULIN; R 1507; TRABECTEDIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANADA; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; FRANCE; GERMANY; HUMAN; HUMAN CELL; HUMAN TISSUE; ITALY; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NETHERLANDS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SOFT TISSUE SARCOMA; SPAIN; SWEDEN; TREATMENT DURATION; TREATMENT RESPONSE; UNITED KINGDOM; UNITED STATES;

EID: 84867128772     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds070     Document Type: Article

References (21)

1. Fletcher CDM, Unni KK, Mertens F. (eds): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone Lyon, France: IARC Press 2002.
2. Ducimetiere F, Lurkin A, Ranchere-Vince R et al. Incidence of Sarcoma histiotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One 2011; 6(8): e20294. Published on August 3, 2011. doi:10.1371/journal.pone.0020294.
3. Wimber C, Leithner A, Zielonke A et al. Increasing incidence rates of soft tissues sarcoma? A population-based epidemiologic study and literature review. Ann Oncol 2010; 21: 1106-1121.
4. US National Institutes of Health. SEER Stat Fact Sheets: Soft Tissue Including Heart. National Cancer Institute, Surveillance Epidemiology and End Results. http// seer.cancer.gov/statfacts/html/soft.html (10 March 2012, date last accessed).
5. Coindre JM, Terrier P, Guillou L et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas. Cancer 2001; 91: 1914-1926.
6. Casali PG, Blay JY. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5): v198-v203.
7. NCCN Clinical Practice Guidelines in Oncology. Soft Tissue Sarcoma, version 1 2011; http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (10 March 2012, date last accessed).
8. Grimer R, Judson I, Peake D, Seddon B. Guidelines for the management of soft tissue sarcomas. Sarcoma 2010. Accepted February 3, 2010. Article ID 506182, doi:10.1155/2010/506182.
9. Krikelis D, Judson I. Role of chemotherapy in the management of soft tissue sarcomas. Expert Rev Anticancer Ther 2010; 10 (2): 249-260.
10. Maki RG, Wathen JK, Patel SR et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 2007; 25 (19): 2755-2763.
11. Duffaud F, Bui BN, Penel N et al. A FNCLCC French Sarcoma Group-GETO multicenter randomized phase II study of gemcitabine (G) versus gemcitabine and docetaxel (G+D) in patients with metastatic or relapsed leiomyosarcoma (LMS). J Clin Oncol 2008; 26 (Suppl): (Abstr 10511).
12. Schlemmer M, Reichardt P, Verweij J et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 2008; 44: 2433-2436.
13. Demetri GD, Chawla SP, von Mehren M et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27: 4188-4196.
14. Gross F, Sanfillippo R, Virdis E et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol 2009; 20(8):1439-1444.
15. Karavasilis V, Seddon BM, Ashley S et al. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma. Cancer 2008; 112: 1585-1590.
16. Minchom A, Jones RL, Fisher C et al. Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma. Sarcoma 2010. Published May 20, 2010. Article ID 264360, doi:10.1155/2010/264360.
17. Reichardt P, Leahy M, Garcia del Muro X et al. Quality of life and utility in patients with metastatic soft tissue and bone sarcoma: the sarcoma treatment and burden of illness in North America and Europe (SABINE) study. Sarcoma 2012; in press.
18. Chawla SP, Blay JY. Ray-Coquard I et al. Results of the phase III, placebocontrolled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). J Clin Oncol 2011; 29 (Suppl): (Abstr 10005).
19. Product Information: Epirubicin Hydrochloride IV Injection, Epirubicin Hydrochloride IV Injection Irvine, CA: Teva Parenteral Medicines, Inc. 2010.
20. Italiano A, Mathoulin-Pelissier S, Cesne AL et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer 2011; 117: 1049-1054.
21. Reichardt P, Tilgner J, Hohenberger P, Dorken P. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol 1998; 16: 1438-1443.